Stock QNCX QUINCE THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Quince Therapeutics, Inc.

Equities

QNCX

US22053A1079

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-07-05 pm EDT 		5-day change 1st Jan Change
0.7293 USD +4.08% Intraday chart for Quince Therapeutics, Inc. -2.76% -30.54%
Jun. 26 Transcript : Quince Therapeutics, Inc. - Special Call
Jun. 25 Quince Therapeutics Doses First Patient in Phase 3 Trial of EryDex to Treat Ataxia-Telangiectasia MT

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Transcript : Quince Therapeutics, Inc. - Special Call
Quince Therapeutics Doses First Patient in Phase 3 Trial of EryDex to Treat Ataxia-Telangiectasia
MT
Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of EryDex for the Treatment of Ataxia-Telangiectasia
BU
Quince Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of Erydex for the Treatment of Ataxia-Telangiectasia
CI
Transcript : Quince Therapeutics, Inc. - Shareholder/Analyst Call
Quince Therapeutics Receives U.S. FDA Fast Track Designation for EryDex System
BU
Quince Therapeutics, Inc. Receives U.S. FDA Fast Track Designation for EryDex System
CI
Quince Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Quince Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
BU
Quince Therapeutics to Present at The Citizens JMP Life Sciences Conference
BU
Quince Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Quince Therapeutics Provides Business Update and Reports Fourth Quarter and Fiscal 2023 Financial Results
BU
Transcript : Quince Therapeutics, Inc. - Special Call
North American Morning Briefing : Markets Steady -2-
DJ
Quince Therapeutics Launches Scientific Advisory Board
BU
Quince Therapeutics, Inc. Launches Scientific Advisory Board
CI
Quince Therapeutics Appoints Former Reata Pharmaceuticals Chief R&D Officer Dr. Rajiv Patni to its Board of Directors
BU
Quince Therapeutics, Inc. Appoints Rajiv Patni to Its Board of Directors
CI
Quince Therapeutics to Present at Oppenheimer 34th Annual Healthcare Life Sciences Conference
BU
Quince Therapeutics to Participate at Investor Events in January 2024
BU
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. QNCX Stock
  4. News Quince Therapeutics, Inc.